Published in:
Open Access
01-12-2022 | Chronic Myeloid Leukemia | Correction
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Authors:
Qian Jiang, Zongru Li, Yazhen Qin, Weiming Li, Na Xu, Bingcheng Liu, Yanli Zhang, Li Meng, Huanling Zhu, Xin Du, Suning Chen, Yang Liang, Yu Hu, Xiaoli Liu, Yongping Song, Lichuang Men, Zi Chen, Qian Niu, Hengbang Wang, Ming Lu, Dajun Yang, Yifan Zhai, Xiaojun Huang
Published in:
Journal of Hematology & Oncology
|
Issue 1/2022
Login to get access
Excerpt
The original article [
1] contained three erroneous citations and other minor typesetting errors in the text which have since been amended. …